Diuretics & Masking Agents (Furosemide, Hydrochlorothiazide, Spironolactone, Acetazolamide & Probenecid)
Diuretics & Masking Agents (Furosemide, Hydrochlorothiazide, Spironolactone, Acetazolamide & Probenecid) is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Diuretics & Masking Agents (Furosemide, Hydrochlorothiazide, Spironolactone, Acetazolamide & Probenecid)
Common Names, Synonyms & Classifications: Furosemide (Frusemide) IP; Torasemide IP; Hydrochlorothiazide IP; Chlorthalidone IP; Spironolactone IP; Acetazolamide IP; Mannitol IP; Probenecid; Desmopressin
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B18)
2. Pharmacological Class
Renal Tubular Natriuretic/Diuretic Agents, Urinary Diluters & Organic Anion Transporter (OAT) Masking Agents
3. Mechanism of Action
Diuretics inhibit specific renal nephron sodium/water transporters: Loop diuretics (Furosemide, Torasemide) block NKCC2 in the thick ascending limb; Thiazides (Hydrochlorothiazide, Chlorthalidone) block NCC in the distal convoluted tubule; Spironolactone/Eplerenone antagonise aldosterone receptors in the collecting duct; Acetazolamide inhibits proximal tubular Carbonic Anhydrase. Probenecid competitively inhibits renal proximal tubular Organic Anion Transporters (OAT1/OAT3), blocking active tubular secretion of acidic drug metabolites (such as conjugated anabolic steroid glucuronides).
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Acute urinary water and electrolyte excretion. Anti-Doping & Clinical Reality: Diuretics DO NOT enhance athletic strength or endurance—in fact, diuretic-induced hypovolaemia and electrolyte depletion severely impair thermoregulation, cardiac output, VO₂max, and muscular power! They are abused in sport for two illicit reasons: (1) rapid artificial dehydration to 'make weight' in weight-class sports (wrestling, boxing, judo, weightlifting), and (2) diluting urine specific gravity or blocking renal tubular excretion to mask prohibited substances.
5. Quality of Scientific Evidence
Evidence Assessment: PROHIBITED AT ALL TIMES (WADA S5) — Detrimental to Exercise Performance; High Risk of Fatal Hypokalaemic Arrhythmia and Heat Collapse
6. Approved Medical Uses (Where Applicable)
Furosemide IP, Hydrochlorothiazide IP, Spironolactone IP, Acetazolamide IP, and Mannitol IP are essential NLEM 2022 / IP 2022 prescription medicines for heart failure, hypertension, cirrhotic ascites, cerebral oedema, glaucoma, and acute mountain sickness.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Illicit pre-weigh-in dehydration or urine dilution; also found as undeclared adulterants in 'herbal slimming teas' and 'water pills' (often spiked with furosemide or hydrochlorothiazide). Note: Under WADA S5, an athlete in a weight-category sport generally cannot obtain a Therapeutic Use Exemption (TUE) for a diuretic!
8. Adverse Effects & Serious Safety Risks
Severe hypovolaemia, orthostatic hypotension, syncope, acute kidney injury (pre-renal azotaemia), life-threatening electrolyte derangements (hypokalaemia, hyponatraemia, hypomagnesaemia with loop/thiazide diuretics; hyperkalaemia with spironolactone), cardiac arrhythmias (Torsades de Pointes), hyperuricaemia/gout, ototoxicity (high-dose Furosemide), and fatal exertional heatstroke.
9. Contraindications & Precautions
Anuria, severe hyponatraemia/hypokalaemia, hypovolaemia/dehydration, sulfonamide hypersensitivity (for loop/thiazide/carbonic anhydrase diuretics), and non-medical weight cutting in sport.
10. Drug Interactions
Loop/thiazide-induced hypokalaemia markedly increases Digoxin toxicity and QTc-prolonging drug arrhythmias; NSAIDs blunt diuretic natriuresis and precipitate acute kidney injury ('triple whammy' with ACEi/ARB + diuretic + NSAID); diuretics reduce renal Lithium clearance, causing lithium neurotoxicity.
11. Clinical & Laboratory Monitoring Considerations
In clinical patients: Serum electrolytes (Na⁺, K⁺, Mg²⁺, HCO₃⁻), blood urea, serum creatinine, blood pressure, and fluid balance.
12. Dependence, Misuse or Withdrawal Concerns
Psychological abuse in eating disorders and weight-cycling athletes, leading to rebound secondary hyperaldosteronism and oedema upon withdrawal.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Prescription-only Schedule H medicines under the Drugs and Cosmetics Act, 1940 and Indian Pharmacopoeia (IP 2022) ([3.11]–[3.15]).
14. Official WADA Prohibited-List Status
PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S5 (Diuretics and Masking Agents — Specified Substances, including desmopressin, probenecid, plasma expanders, and all diuretics except topical ophthalmic dorzolamide/brinzolamide and local dental felypressin).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026